Sotorasib combined with 3-methyladenine for the treatment of KRAS G12C-mutant pancreatic cancer and its underlying mechanisms
Yukun Li, Mengmeng Zhou, Jingjing Pan, Haochen Su, Mengke Song, Zujiao Guan, Danmai Zhao, Xiaoxin Zhao, Yiqi Zhao, Pu Chen, Shu Zhang, Ying Lv · 2026
Read Sotorasib combined with 3-methyladenine for the treatment of KRAS G12C-mutant pancreatic cancer and its underlying mechanisms by Yukun Li, Mengmeng Zhou, Jingjing Pan, Haochen Su, Mengke Song, Zujiao Guan, Danmai Zhao, Xiaoxin Zhao, Yiqi Zhao, Pu Chen, Shu Zhang, Ying Lv (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13223805.txt.
Description
Yukun Li and co-authors pair a KRAS-blocking drug with an autophagy inhibitor against pancreatic cancer carrying the G12C mutation, in a 2026 study spanning cell and animal experiments. Sotorasib was developed for this exact mutation, yet pancreatic tumors have rarely been its target. Pancreatic cancer still kills most patients within years, with five-year survival near ten percent.
The team reports that sotorasib switches on a protective self-eating process, autophagy, early in treatment, which blunts its killing power. Adding 3-methyladenine, a blocker of that early autophagy step, strengthened the antitumor effect in their models. The combination, they argue, deserves development as a strategy for this hard-to-treat mutation group.
Catalog record
| CREATOR | Yukun Li, Mengmeng Zhou, Jingjing Pan, Haochen Su, Mengke Song, Zujiao Guan, Danmai Zhao, Xiaoxin Zhao, Yiqi Zhao, Pu Chen, Shu Zhang, Ying Lv |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 66 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |